89Zr-Radiopharmaceutical
89Zr is a widely utilized radionuclide in radiopharmaceutical development, known for its long half-life and suitability for PET imaging in immuno-oncology and targeted therapies. Alfa Cytology provides comprehensive preclinical solutions, from radioisotope labeling and medicinal chemistry optimization to pharmacological evaluation and preclinical studies, enabling seamless progression from proof-of-concept to preclinical development.
Overview of 89Zr-Based Radiopharmaceuticals
Zirconium-89 is a positron-emitting radionuclide with unique properties that make it highly suited for advanced molecular imaging. Its long half-life of approximately 78 hours allows for extended imaging windows, making it ideal for tracking the behavior of biomolecules such as antibodies and proteins. Combined with its compatibility with PET imaging, 89Zr plays a pivotal role in preclinical research and the development of precision diagnostics.
89Zr in Precision Medicine
Zirconium-89 is highly effective in precision medicine, particularly for its ability to label large biomolecules such as antibodies and proteins. This enables targeted imaging and therapy, offering detailed insights into the biological behavior of diseases at the molecular level. By providing accurate, real-time visualization of therapeutic agents, 89Zr enhances the ability to monitor treatment response and optimize patient-specific therapies, thereby advancing personalized medicine.
Fig.1. Specific tumor uptake of 89Zr-AMG211 in LS174T tumor-bearing mice. (Waaijer, S.J. et al., 2018)
Several 89Zr-labeled antibody drugs are progressing through clinical trials, signaling a promising market for targeted therapeutic diagnostics. Notably, 89Zr-labeled trastuzumab (Herceptin) has gained traction for imaging HER2-positive breast cancer, providing oncologists with real-time insights into patient responses to immunotherapy.
Our Services
Alfa Cytology provides a comprehensive 89Zr-labeled drug and imaging agent development service, covering each critical step from radiolabeling to preclinical analysis. The wide-reaching service portfolio covers everything from the development of antibody drugs, imaging agents, and tracers; thus, it makes the entire process run from discovery through preclinical research.
89Zr-based Radiopharmaceutical Development Services
Alfa Cytology is a preclinical contract research provider specializing in the development of PET imaging agents and tracers for accurate diagnostics. We design and optimize radiopharmaceuticals with high sensitivity and excellent background suppression, ensuring reliable preclinical data for the advancement of therapeutic development.
89Zr Labeling and Optimization
We optimize the 89Zr labeling techniques for high efficiency, drug stability, and produce high-purity and target-specific radiolabeled molecules. Our versatile labeling strategies serve the various therapeutic and diagnostic development needs.
In Vivo PD and Biodistribution Analysis
By applying advanced animal models and appropriate PET imaging platforms, Alfa Cytology can deliver high-resolution biodistribution and pharmacokinetic data to enable clients to assess targeting efficacy and optimize dosing.
Multi-Layered Data Analysis
Comprehensive pharmacokinetic profiling and efficacy distribution mapping were performed on data from the current study and are instructive regarding in vivo performance for further dose design and preclinical decisions on 89Zr-labeled drugs.
89Zr-Radiopharmaceuticals Related Services
Alfa Cytology offers comprehensive services for 89Zr radiopharmaceuticals, including labeling a wide range of molecules and providing preclinical experimental services. These services are designed to help researchers assess the in vivo distribution, metabolism, and targeting effects of radiopharmaceuticals.
Imaging and Analysis Services
Our specialized services provide cutting-edge solutions for preclinical research and development across multiple therapeutic areas.
Preclinical Imaging Solutions for Oncology Therapeutics
We offer advanced imaging services utilizing 89Zr-labeled antibody drugs for targeted oncology research and therapeutic development. Our capabilities enable precise tumor visualization and therapeutic response monitoring, supporting the development of novel therapeutics.
Preclinical Immunotherapy Development Support
Our preclinical imaging services employ 89Zr-labeled agents to monitor immunotherapy distribution and immune system interactions. These services provide critical data for researchers developing next-generation immunotherapies and evaluating their mechanisms of action.
Preclinical Imaging Solutions for Neurodegenerative Disorders
We provide sensitive preclinical imaging solutions using 89Zr-based tracers for neurodegenerative disease research. Our services support the development of diagnostic tools and therapeutic monitoring systems for conditions including Alzheimer's, Parkinson's, and other neurological disorders.
To learn more about Alfa Cytology's 89Zr radiopharmaceutical and imaging agent development services or to discuss specific project needs in greater detail, do not hesitate to contact us. Our experts are here to provide the technical consultation and project support needed to achieve your drug development objectives faster and with greater efficiency.
Reference
- Waaijer, S.J., et al. (2018). Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors. Clinical Cancer Research. 24, 4988 - 4996.
For research use only. Not intended for any clinical use.
Related Service
